ClinicalTrials.gg
CompletedNCT02310672REPAIRUpdated Mar 30, 2025Results posted

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

A Phase 4 interventional study of Macitentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 41 sites in 12 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing macitentan in Pulmonary Arterial Hypertension — 1 open to participants now, 2 under way, 2 of them phase 3. macitentan · Pulmonary Arterial Hypertension.

Enrollment
11th of 18
89 · median 156
Started
2015
with 2 others
Phase 4
2 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
15 of 18
Actelion

Among the 18 studies testing macitentan in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 2 in phase 4, and was the 9th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing macitentan in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About macitentan

macitentan: first FDA approval 2013 (OPSUMIT), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing macitentan in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each patient can participate in no sub-study or in one sub-study. The sub-studies are: (1) metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the RHC); (3) Echo sub-study.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to any study-mandated procedure
  2. Symptomatic pulmonary arterial hypertension (PAH)
  3. World Health Organization (WHO) Functional Class (FC) I to III
  4. PAH etiology belonging to one of the following groups according to Nice classification:

    • Idiopathic PAH
    • Heritable PAH
    • Drug- and toxin-induced PAH
    • PAH associated with congenital heart diseases: only simple (atrial septal defect, ventricular septal defect, patent ductus arteriosus) congenital systemic to pulmonary shunts at least 2 year post surgical repair
  5. Hemodynamic diagnosis of PAH confirmed by right heart catheterization (RHC) during screening showing:

    • mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and
    • PCWP (pulmonary capillary wedge pressure) or left ventricular end diastolic pressure (LVEDP) ≤ 12 mmHg and pulmonary vascular resistance (PVR) ≥ 4 Wood Units (WU) (320 dyn.sec.cm-5) or
    • 12 mmHg ≤ PCWP or LVEDP ≤ 15 mmHg and PVR ≥ 6WU (480 dyn.sec.cm-5)
  6. 6-minute walk distance (6MWD) ≥ 150 m during screening
  7. For patients treated with oral diuretics, treatment dose must have been stable at least 1 month prior to RHC during the screening period
  8. For patients treated with phosphodiesterase type-5 (PDE-5) inhibitors, treatment dose must have been stable at least 3 months prior to RHC during the screening period
  9. For patients treated with beta blockers, treatment dose must have been stable at least 1 month prior to the RHC during the screening period
  10. Men or women ≥18 and \< 65 years
  11. Women of (defined in protocol) must:

    • Have a negative serum pregnancy test during screening and a negative urine pregnancy test on Day 1, and
    • Agree to use reliable methods of (defined in protocol) from screening up to 30 days after study treatment discontinuation, and
    • Agree to perform monthly pregnancy tests up to 30 days after study treatment discontinuation

Exclusion criteria

Exclusion Criteria:

  1. Body weight \< 40 kg
  2. (BMI) > 35kg/m2. For patients with 30kg/m2 \< BMI \< 35kg/m2, an eligibility form will be submitted to a Steering Committee member who will reserve the right to exclude the patient.
  3. Pregnancy, breastfeeding or intention to become pregnant during the study
  4. Recently started (\< 8 weeks prior to signature) or planned cardio-pulmonary rehabilitation program
  5. Known concomitant life-threatening disease with a \< 12 months
  6. Any condition likely to affect protocol or treatment compliance
  7. Hospitalization for PAH within 3 months prior to informed consent signature
  8. Left atrial volume indexed for body surface area ≥ 43mL/m2 by echocardiography or cardiac MRI
  9. Valvular disease grade 2 or higher
  10. History of pulmonary embolism or deep vein thrombosis
  11. Documented moderate to severe
  12. Documented moderate to severe restrictive lung disease
  13. Historical evidence of significant coronary artery disease established by:

    • History of myocardial infarction or
    • More than 50% stenosis in a coronary artery (by percutaneous coronary intervention or angiography) or
    • Elevation of the ST segment on or
    • History of coronary artery bypass grafting or
    • Stable angina
  14. Diabetes mellitus
  15. Moderate to severe renal insufficiency (calculated \< 60 mL/min/1.73 m2)
  16. Cancer
  17. Systolic blood pressure \< 90 mmHg
  18. Severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total > 3 × (ULN) accompanied by an (AST) elevation > ULN at Screening.
  19. \< 100g/L
  20. AST and/or alanine aminotransferase (ALT) > 3× ULN
  21. Need for dialysis
  22. Responders to acute vasoreactivity test based on medical history
  23. Prior use of endothelin receptor antagonists (ERAs), stimulators of soluble guanylate cyclase or prostacyclin or prostacyclin analogues
  24. Treatment with strong inducers of cytochrome P450 isozyme 3A4 () within 4 weeks prior to study treatment initiation (e.g., carbamazepine, rifampicin, rifabutin, phenytoin and St. John's Wort)
  25. Treatment with strong inhibitors of CYP3A4 within 4 weeks prior to study treatment initiation (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
  26. Treatment with another drug (planned, or taken within the 3 months prior to study treatment initiation).
  27. to any ERA or any of the formulation of macitentan (lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, polyvinyl alcohol, polysorbate, titanium dioxide, talc, xanthan gum, and lecithin soya)
  28. Claustrophobia
  29. Permanent cardiac pacemaker, automatic internal cardioverter
  30. Metallic implant (e.g., defibrillator, neurostimulator, hearing aid, permanent use of infusion device)
  31. Atrial fibrillation, multiple premature ventricular or atrial contractions, or any other condition that would interfere with proper cardiac gating during MRI.
  32. For patients enrolling in the metabolism sub-study only: glucose intolerance
  33. For patients enrolling in the sub-study only: PAH etiology belonging to Nice classification 1.4.4: PAH associated with congenital heart diseases
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Macitentan

    All patients take open-label macitentan 10mg o.d.

    Drug: Macitentan

Interventions

  • All patients take open-label macitentan 10mg o.d.

    Also known as: ACT-064992

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26

    Change from baseline in RVSV assessed by cardiac magnetic resonance imaging (MRI) from pulmonary artery flow was reported at Week 26. Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.

    Time frame: Baseline and Week 26

  2. Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)

    Ratio of Week 26 to baseline PVR as assessed by RHC was reported. PVR represents the resistance against which the right ventricle needs to pump. PVR is determined by right heart catheterization (RHC). PVR was calculated as 80\*(Mean pulmonary arterial pressure \[mPAP\] -\[Pulmonary capillary wedge pressure {PCWP} or Left ventricular end diastolic pressure {LVEDP} if PCWP not available/cardiac output \[CO\]). Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26

    Change from baseline to Week 26 in RVEDV assessed by cardiac MRI was reported.

    Time frame: Baseline to Week 26

  2. Change From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26

    Change from baseline to Week 26 in RVESV assessed by cardiac MRI was reported.

    Time frame: Baseline to Week 26

  3. Change From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume)

    Change from baseline to Week 26 in RVEF based on pulmonary artery flow assessed by cardiac MRI was reported.

    Time frame: Baseline to Week 26

  4. Change From Baseline in Right Ventricle (RV) Mass to Week 26

    Change from baseline to Week 26 in RV mass assessed by cardiac MRI was reported.

    Time frame: Baseline to Week 26

  5. Change From Baseline in Six-minutes Walk Distance (6MWD) to Week 26

    6MWD is a non-encouraged test performed in a 30 meter (m) long flat corridor, where the participant is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. This test is used to assess exercise capacity. The test was performed about 30 minutes after study drug administration. Any increase in the walk distance was considered improvement from baseline.

    Time frame: Baseline to Week 26

  6. Change From Baseline in World Health Organization Functional Class (WHO FC) to Week 26

    WHO FC is a classification which reflects disease severity based on symptoms. WHO Functional Classification of pulmonary hypertension comprises of Class I (participants with pulmonary hypertension but without resulting limitation of physical activity), II (participants with pulmonary hypertension resulting in slight limitation of physical activity), III (participants with pulmonary hypertension resulting in marked limitation of physical activity) and IV (participants with pulmonary hypertension with inability to carry out any physical activity without symptoms). Changes from baseline to Week 26 included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or unchanged/stable (same FC at baseline and at the post-baseline time point).

    Time frame: Baseline to Week 26

07

Results

Posted Sep 24, 2020
Limitations and caveats
Due to the open-label non-comparative design of study, it cannot be excluded that 6MWD and WHO FC could have been influenced by participants' knowledge that they did receive an active treatment whose efficacy had already been demonstrated.

Participant flow

Participant flow — Overall Study
MilestoneMacitentan 10 mg
Started87
Completed72
Not completed15
Withdrew: Death1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1
Withdrew: Sponsor's decision12

Outcome measures

PrimaryChange From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26

Change from baseline in RVSV assessed by cardiac magnetic resonance imaging (MRI) from pulmonary artery flow was reported at Week 26. Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · milliliters (mL)
Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26
milliliters (mL)Macitanten 10 mg
Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 2615.17 ± 2.75
PrimaryRatio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)

Ratio of Week 26 to baseline PVR as assessed by RHC was reported. PVR represents the resistance against which the right ventricle needs to pump. PVR is determined by right heart catheterization (RHC). PVR was calculated as 80\*(Mean pulmonary arterial pressure \[mPAP\] -\[Pulmonary capillary wedge pressure {PCWP} or Left ventricular end diastolic pressure {LVEDP} if PCWP not available/cardiac output \[CO\]). Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.

Time frame:
Baseline and Week 26
Reported as:
Geometric mean · Ratio
Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)
RatioMacitanten 10 mg
Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)0.63 ± 0.11
SecondaryChange From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26

Change from baseline to Week 26 in RVEDV assessed by cardiac MRI was reported.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · mL
Change From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26
mLMacitanten 10 mg
Change From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26-6.22 (-12.50 to 0.07)
SecondaryChange From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26

Change from baseline to Week 26 in RVESV assessed by cardiac MRI was reported.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · mL
Change From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26
mLMacitanten 10 mg
Change From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26-16.39 (-20.56 to -12.21)
SecondaryChange From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume)

Change from baseline to Week 26 in RVEF based on pulmonary artery flow assessed by cardiac MRI was reported.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Percentage of blood volume
Change From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume)
Percentage of blood volumeMacitanten 10 mg
Change From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume)10.14 (7.46 to 12.83)
SecondaryChange From Baseline in Right Ventricle (RV) Mass to Week 26

Change from baseline to Week 26 in RV mass assessed by cardiac MRI was reported.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Grams
Change From Baseline in Right Ventricle (RV) Mass to Week 26
GramsMacitanten 10 mg
Change From Baseline in Right Ventricle (RV) Mass to Week 26-10.10 (-13.81 to -6.39)
SecondaryChange From Baseline in Six-minutes Walk Distance (6MWD) to Week 26

6MWD is a non-encouraged test performed in a 30 meter (m) long flat corridor, where the participant is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. This test is used to assess exercise capacity. The test was performed about 30 minutes after study drug administration. Any increase in the walk distance was considered improvement from baseline.

Time frame:
Baseline to Week 26
Reported as:
Least squares mean · Meters
Change From Baseline in Six-minutes Walk Distance (6MWD) to Week 26
MetersMacitanten 10 mg
Change From Baseline in Six-minutes Walk Distance (6MWD) to Week 2638.85 ± 7.37
SecondaryChange From Baseline in World Health Organization Functional Class (WHO FC) to Week 26

WHO FC is a classification which reflects disease severity based on symptoms. WHO Functional Classification of pulmonary hypertension comprises of Class I (participants with pulmonary hypertension but without resulting limitation of physical activity), II (participants with pulmonary hypertension resulting in slight limitation of physical activity), III (participants with pulmonary hypertension resulting in marked limitation of physical activity) and IV (participants with pulmonary hypertension with inability to carry out any physical activity without symptoms). Changes from baseline to Week 26 included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or unchanged/stable (same FC at baseline and at the post-baseline time point).

Time frame:
Baseline to Week 26
Reported as:
Count of participants · Participants
Change From Baseline in World Health Organization Functional Class (WHO FC) to Week 26
ParticipantsMacitanten 10 mg
Missing WHO FC5
Worsened WHO FC1
Unchanged WHO FC35
Improved WHO FC46

Adverse events

Collected over Up to 420 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Macitentan 10 mg1/87 (1.1%)15/87 (17.2%)57/87 (65.5%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventMacitentan 10 mg
PneumoniaInfections and infestations3/87
Acute Myocardial InfarctionCardiac disorders2/87
SepsisInfections and infestations2/87
Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders2/87
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/87
AnaemiaBlood and lymphatic system disorders1/87
Haemolytic AnaemiaBlood and lymphatic system disorders1/87
Iron Deficiency AnaemiaBlood and lymphatic system disorders1/87
Angina PectorisCardiac disorders1/87
Atrial FibrillationCardiac disorders1/87
Most frequent other events
Showing 10 of 15
Most frequent other events
EventMacitentan 10 mg
Oedema PeripheralGeneral disorders19/87
HeadacheNervous system disorders18/87
DizzinessNervous system disorders12/87
Upper Respiratory Tract InfectionInfections and infestations10/87
Haemoglobin DecreasedInvestigations10/87
CoughRespiratory, thoracic and mediastinal disorders10/87
MyalgiaMusculoskeletal and connective tissue disorders9/87
DiarrhoeaGastrointestinal disorders8/87
Nasal CongestionRespiratory, thoracic and mediastinal disorders8/87
PyrexiaGeneral disorders7/87

Baseline characteristics

Safety Set included all screened participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Macitentan 10 mg
Mean45.9 ± 14.48
Sex: Female, Male
Sex: Female, Male(Participants)Macitentan 10 mg
Female70
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Macitentan 10 mg
Hispanic or Latino1
Not Hispanic or Latino72
Unknown or Not Reported14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Macitentan 10 mg
Black or African American1
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
Asian26
White46
Other0
Unknown or Not Reported14
Region of Enrollment
Region of Enrollment(Participants)Macitentan 10 mg
FRANCE14
GERMANY12
ISRAEL2
ITALY3
MALAYSIA8
NETHERLANDS12
RUSSIAN FEDERATION11
SINGAPORE9
UNITED KINGDOM3
UNITED STATES6
Hong Kong7
08

Study locations

41 sites
  • Massachussetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Rudgers New Jersey Medical School
    New Brunswick, New Jersey 08901, United States
  • Cornell University
    New York, New York 10065, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • University of Texas Southwestern Medical
    Dallas, Texas 75390, United States
  • St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Hopital Gabriel Montpied
    Clermont-Ferrand, 63003, France
  • Hôpital Michallon
    La Tronche, 38700, France
  • "CHRU de Lille - Hôpital Albert Calmette "
    Lille Cedex, 59037, France
  • Hopital de Brabois
    Nancy, 54511, France
  • Hôpital Laennec
    Nantes Cedex 01, 44093, France
  • Hôpital Pasteur
    Nice, 06002, France
  • Hôpital Européen Georges-Pompidou
    Paris, 75015, France
  • Medizinische Klinik und Poliklinik II Universitätsklinik Bonn
    Bonn, 53105, Germany
  • Thoraxklinik am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin
    Köln, 50924, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase
    Mainz, 55131, Germany
  • Grantham Hospital, Cardiac Medical Unit
    Hong Kong, 999077, Hong Kong
  • Queen Mary Hospital
    Hong Kong, 999077, Hong Kong
  • United Christian Hospital
    Hong Kong, 999077, Hong Kong
  • Pulmonology institute, Soroka Medical Center
    Beer-Sheva, 84101, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti
    Pavia, 27100, Italy
  • Hospital Pulau Pinang
    George Town, 10990, Malaysia
  • Institut Jantung Negara (National Heart Institute)
    Kuala Lumpur, 50400, Malaysia
  • VU University Medical Center (VUMC)
    Amsterdam, 1081 HV, Netherlands
  • Maastricht UMC+
    Maastricht, 6229, Netherlands
  • St. Antonius Ziekenhuis
    Nieuwegein, 3435 CM, Netherlands
  • Radboud UMC
    Nijmegen, 6525 GA, Netherlands
  • Erasmus University medical Center
    Rotterdam, 3000 CA, Netherlands
  • Russian Cardiology Scientific and Production Complex
    Moscow, 121552, Russian Federation
  • Almazov Federal North-West Medical Research Centre of Department of Health
    Saint Petersburg, 197341, Russian Federation
  • National University Hospital - The Heart Institute - Cardiac Department
    Singapore, 119228, Singapore
  • National Heart Centre (NHC) Singapore
    Singapore, 169609, Singapore
  • Golden Jubilee National Hospital
    Glasgow, G81 4DY, United Kingdom
  • The Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • "Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital"
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Vonk Noordegraaf A, Channick R, Cottreel E, Kiely DG, Marcus JT, Martin N, Moiseeva O, Peacock A, Swift AJ, Tawakol A, Torbicki A, Rosenkranz S, Galie N. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2022 Feb;15(2):240-253. doi: 10.1016/j.jcmg.2021.07.027. Epub 2021 Nov 17. PubMed 34801462 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Sep 2019, 51 months.

Results were first posted in Sep 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2014
First posted
Dec 8, 2014
StartActual
Jun 1, 2015
Primary completionActual
Sep 10, 2019
CompletionActual
Sep 10, 2019
Results first posted
Sep 24, 2020
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02310672
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Jun 1, 2015
Primary completion
Sep 10, 2019
Completion
Sep 10, 2019
Results posted
Sep 24, 2020
Last update
Mar 30, 2025

Study contacts

Loïc Perchenet
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Macitentan

Start the discussion